Last update 01 Nov 2024

Consorci Sanitari del Maresme

Private Company|

Spain

Private Company|

Spain

Last update 01 Nov 2024

Overview

Pipeline

Deal

Translational Medicine

Overview

Clinical Trials associated with Consorci Sanitari del Maresme

NCT04519008 / Not yet recruitingNot Applicable

Effectiveness and Security Testing of a Mobile App (B·RIGHT) for Adolescents With Attention-Deficit/Hyperactivity Disorder and Emotion Dysregulation

To assess the effectiveness and security of a mobile App (beta version) for self-managing emotion dysregulation in a pragmatic randomized controlled trial with 80 adolescents with attention-deficit/hyperactivity disorder comparing 40 patients with treatment as usual (TAU) with 40 patients with TAU plus the mobile App

Start Date01 Oct 2026

Sponsor / Collaborator

Consorci Sanitari del Maresme

NCT04210648 / Not yet recruitingNot Applicable

Effectiveness and Security Testing of a Mobile App for Self-Managing Emotion Dysregulation in a Non-Clinical Population With Borderline Traits: A Randomized Controlled Trial

To assess the effectiveness and security of a mobile App (beta version) for people with borderline traits recruited from a non-clinical population of college students in Barcelona (Spain). The main primary outcome will be the severity of the emotional dysregulation. Forty participants will use the mobile app over 6 months. This group while be compared at post-treatment and at 3-month follow-up with other 40 participants (control group) with any intervention.

Start Date01 Sep 2026

Sponsor / Collaborator

Consorci Sanitari del Maresme

[+1]

NCT04211753 / RecruitingNot Applicable

Effectiveness and Security Testing of a Mobile App (B·RIGHT) for Self-managing Emotional Crises in People With Borderline Personality Disorder: A Pragmatic Randomized Controlled Trial

To assess the effectiveness and security of a mobile App (beta version) for self-managing emotional crisis in a pragmatic randomized controlled trial with 80 patients with borderline personality disorder (40 patients with treatment as usual, TAU) versus 40 patients with TAU plus the mobile App)

Start Date01 Feb 2025

Sponsor / Collaborator

Consorci Sanitari del Maresme

100 Clinical Results associated with Consorci Sanitari del Maresme

0 Patents (Medical) associated with Consorci Sanitari del Maresme

194

Literatures (Medical) associated with Consorci Sanitari del Maresme

01 Dec 2024·Public Health

Frailty trends in Catalonia 2017–2021: An epidemiological study with 1.5 million people aged ≥65 years

Article

Author: Cabré, Mateu ; Fortuny, Aida ; Serra-Colomer, Júlia ; Muñoz, Laura ; Serra-Prat, Mateu ; Burdoy, Emili ; Martínez-Cerdá, Juan Francisco ; Lavado, Àngel ; Moreno-Carmona, Ma Rosario ; Papiol, Mònica

OBJECTIVESKnowledge of frailty prevalence and incidence trends over time is essential for planning the necessary health and social resources. The objective of this study was to assess frailty prevalence, incidence, reversibility and mortality rates, and trends for the population aged ≥65 years in Catalonia over the period 2017-2021.STUDY DESIGNLongitudinal epidemiological study.METHODSAn observational longitudinal 5-year study (1 January 2017 to 31 December 2021) of the population aged ≥65 years in Catalonia (approximately 1.5 million individuals) was performed using retrospectively collected data from different health databases. Frailty status was evaluated using the electronic Screening Index of Frailty (e-SIF) and categorised as robust, pre-frail, moderately frail or severely frail.RESULTSStandardised frailty prevalence rates were 10.5 % (2017), 11.8 % (2018), 13.1 % (2019), 12.9 % (2020) and 14.3 % (2021) [p-value for trend = 0.010]. Standardised frailty incidence rates per 1000 non-frail persons/year were 35 (2018), 36 (2019), 28 (2020) and 33 (2021) [p-value for trend = 0.492]. Both prevalence and incidence were higher in women and increased with age. Standardised frailty reversibility rates per 1000 frail persons/year were 123 (2018), 108 (2019) and 121 (2020) [p-value for trend = 0.406], and decreased with age. Standardised mortality rates for frail individuals per 1000 frail persons/year were 93 (2018), 84 (2019) and 110 (2020) [p-value for trend = 0.555], and increased with frailty severity.CONCLUSIONSFrailty prevalence in Catalonia increased by 36 % between 2017 and 2021; however, no clear trend was evident for frailty incidence and reversibility, while results for mortality were likely to have been influenced by the COVID-19 pandemic.

23 Jul 2024·Neurology

Influence of Hospital Type on Outcomes of Patients With Acute Spontaneous Intracerebral Hemorrhage

Article

Author: Cánovas, David ; Rodríguez, Blanca Lara ; Krupinski, Jerzy ; Díaz, Garbiñe Ezcurra ; Pérez, Jordi ; Steinhauer, Eva Giralt ; Amaro, Sergio ; Guanyabens, Nicolau ; Fagundez, Olga ; Ramos-Pachón, Anna ; Quesada, Helena ; Zaragoza, Jose ; Prats-Sanchez, Luis ; Catena, Esther ; Camps-Renom, Pol ; Wenger, Denisse ; Núñez-Guillén, Ana ; De La Ossa, Natalia Pérez ; Rodriguez-Luna, David ; Silva, Yolanda ; Vázquez-Justes, Daniel ; Gomez-Choco, Manuel ; Guasch-Jiménez, Marina ; Lambea-Gil, Álvaro ; Marti-Fabregas, Joan ; Abilleira, Sònia ; Pancorbo, Olalla ; Puig, Isabel ; Salvat-Planas, Mercè ; Costa, Xavier ; Paipa-Merchan, Andrés ; Marin, Rebeca ; Llull, Laura ; Cocho, Dolores ; Rodríguez-Villatoro, Noelia ; Rodriguez-Campello, Ana ; Casadevall, Marc Puig ; Martinez-Domeño, Alejandro ; Calvo, Núria Matos ; Seró, Laia

BACKGROUND AND OBJECTIVESWhether the outcome of patients with spontaneous intracerebral hemorrhage (ICH) differs depending on the type of hospital where they are admitted is uncertain. The objective of this study was to determine influence of hospital type at admission (telestroke center [TSC], primary stroke center [PSC], or comprehensive stroke center [CSC]) on outcome for patients with ICH. We hypothesized that outcomes may be better for patients admitted to a CSC.METHODSThis is a multicenter prospective observational and population-based study of a cohort of consecutively recruited patients with ICH (March 2020-March 2022). We included all patients with spontaneous ICH in Catalonia (Spain) who had a pre-ICH modified Rankin scale (mRS) score of 0-3 and who were admitted to the hospital within 24 hours of onset. We compared patients admitted to a TSC/PSC (n = 641) or a CSC (n = 1,320) and also analyzed the subgroup of patients transferred (n = 331) or not transferred (n = 310) from a TSC/PSC to a CSC. The main outcome was the 3-month mRS score obtained by blinded investigators. Outcomes were compared using adjusted ordinal logistic regression to estimate the common odds ratio (OR) and 95% CI for a shift in mRS scores. A propensity score matching (PSM) analysis was performed for the subgroup of transferred patients.RESULTSRelevant data were obtained from 1961 of a total of 2,230 patients, with the mean (SD) age of 70 (14.1) years, and 713 (38%) patients were women. After adjusting for confounders (age, NIH Stroke Scale score, intraventricular hemorrhage, hematoma volume, and pre-ICH mRS score), type of hospital of initial admission (CSC vs TSC/PSC) was not associated with outcome (adjusted common OR 1.13, 95% CI 0.93-1.38). A PSM analysis indicated that transfer to a CSC was not associated with more favorable outcomes (OR 0.77, 95% CI 0.55-1.10; p = 0.16).DISCUSSIONIn this population-based study, we found that, after adjusting for confounders, hospital types were not associated with functional outcomes. In addition, for patients who were transferred from a TSC/PSC to a CSC, PSM indicated that outcomes were similar to nontransferred patients. Our findings suggest that patient characteristics are more important than hospital characteristics in determining outcome after ICH.TRIAL REGISTRATION INFORMATIONClinicalTrials.gov Identifier: NCT03956485.

01 Jul 2024·Brain, Behavior, and Immunity

Association of symptom severity and cerebrospinal fluid alterations in recent onset psychosis in schizophrenia-spectrum disorders – An individual patient data meta-analysis

Article

Author: Yakimov, Vladislav ; Hasan, Alkomiet ; Benros, Michael E ; Dobrowolny, Henrik ; Steiner, Johann ; Meyer-Lotz, Gabriela ; Hansen, Niels ; Siafis, Spyridon ; Falkai, Peter ; Raabe, Florian ; Mortazavi, Matin ; Wagner, Elias ; Yeeles, Ksenija ; Siskind, Dan ; Boix, Ester ; Campana, Mattia ; Jeppesen, Rose ; Jäger, Iris ; Leucht, Stefan ; Heming, Michael ; Malchow, Berend ; Meyer Zu Hörste, Gerd ; Moussiopoulou, Joanna ; Maurus, Isabel ; Lennox, Belinda ; Halstead, Sean ; Giné-Servén, Eloi ; Labad, Javier ; Warren, Nicola ; Löhrs, Lisa ; Strube, Wolfgang

Neuroinflammation and blood-cerebrospinal fluid barrier (BCB) disruption could be key elements in schizophrenia-spectrum disorderś(SSDs) etiology and symptom modulation. We present the largest two-stage individual patient data (IPD) meta-analysis, investigating the association of BCB disruption and cerebrospinal fluid (CSF) alterations with symptom severity in first-episode psychosis (FEP) and recent onset psychotic disorder (ROP) individuals, with a focus on sex-related differences. Data was collected from PubMed and EMBASE databases. FEP, ROP and high-risk syndromes for psychosis IPD were included if routine basic CSF-diagnostics were reported. Risk of bias of the included studies was evaluated. Random-effects meta-analyses and mixed-effects linear regression models were employed to assess the impact of BCB alterations on symptom severity. Published (6 studies) and unpublished IPD from n = 531 individuals was included in the analyses. CSF was altered in 38.8 % of individuals. No significant differences in symptom severity were found between individuals with and without CSF alterations (SMD = -0.17, 95 %CI -0.55-0.22, p = 0.341). However, males with elevated CSF/serum albumin ratios or any CSF alteration had significantly higher positive symptom scores than those without alterations (SMD = 0.34, 95 %CI 0.05-0.64, p = 0.037 and SMD = 0.29, 95 %CI 0.17-0.41p = 0.005, respectively). Mixed-effects and simple regression models showed no association (p > 0.1) between CSF parameters and symptomatic outcomes. No interaction between sex and CSF parameters was found (p > 0.1). BCB disruption appears highly prevalent in early psychosis and could be involved in positive symptomś severity in males, indicating potential difficult-to-treat states. This work highlights the need for considering BCB breakdownand sex-related differences in SSDs clinical trials and treatment strategies.

100 Deals associated with Consorci Sanitari del Maresme

100 Translational Medicine associated with Consorci Sanitari del Maresme

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 26 Dec 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Consorci Sanitari del Maresme

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 26 Dec 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing